Hv1 inhibition rescues AD pathology by restoring microglial mitochondrial function and enhancing mitochondrial transfer

Jiayuan Lin, Huayun Han, Kexin Wu, Xingyu Wu, Juwen Shen, Yiqing Mo, Qiansen Zhang, Huaiyu Yang, Zhihua YuExperimental 2025 · DOI

TL;DR

This study identifies the hydrogen voltage-gated channel 1 (Hv1) as a key player in microglial mitochondrial dysfunction in Alzheimer's Disease (AD). Inhibiting Hv1 with a novel compound, YHV98-4, not only restores mitochondrial function in microglia but also enhances their ability to transfer healthy mitochondria to neurons, ultimately rescuing AD pathology and improving cognitive function in mouse models.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is characterized by the accumulation of hyperphosphorylated tau and neuroinflammation, with microglia playing a central role in these processes. However, the precise mechanisms by which microglia's own mitochondria become dysfunctional in AD, and how this contributes to disease progression, remain unclear. This dysfunction is a significant hurdle for developing effective AD therapies. This paper investigates the role of the hydrogen voltage-gated channel 1 (Hv1), a proton channel found in microglia, in microglial mitochondrial health and its contribution to AD pathology.

Methods

The researchers employed a multi-pronged approach:

  • Animal Models: They used AD mouse models (3xTg mice and AAV-hTAU injected mice) and Hvcn1 knockout mice to study the role of Hv1 in vivo.
  • Cell Culture: BV2 microglial cells and primary neuronal/microglial cultures were used to investigate cellular mechanisms.
  • Pharmacological Intervention: A specific Hv1 inhibitor, YHV98-4, was synthesized and tested for its therapeutic effects.
  • Molecular and Cellular Assays: A wide range of techniques were used, including:
  • Immunofluorescence and Immunohistochemistry: To visualize protein expression (e.g., Hv1, Iba1, NeuN, AT8, GFAP, CD4, CD8, CD44, NOX2, MAP2) and cellular morphology.
  • Western Blotting: To quantify protein levels (e.g., AT8 monomers/oligomers, LC3).
  • Mitochondrial Function Assays: Measuring mitochondrial membrane potential (MMP), ATP production, mitochondrial ROS (mtROS), and mitochondrial complex activity (Complex I and V).
  • Autophagy and Mitophagy Assays: Using fluorescent reporters to assess autophagic flux and mitophagy.
  • Phagocytosis Assays: Using fluorescent beads to measure microglial phagocytic capacity.
  • RNA Sequencing (RNA-seq): To analyze global gene expression changes in microglia.
  • Behavioral Tests: Morris Water Maze (MWM), Novel Object Recognition (NOR), and Y-maze tests to assess cognitive function.
  • Mitochondrial Transfer Assays: Using fluorescently labeled mitochondria to track their transfer between cells.
  • 3D Reconstruction: To analyze microglial morphology in detail.

Datasets

  • Animal Data: Data generated from experiments on C57BL/6 mice, Hvcn1 knockout mice, and 3xTg AD model mice.
  • Human Data: Publicly available human single-nucleus RNA-seq data of aged controls and sporadic AD patients from the Seattle AD Brain Cell Atlas was used for analysis of Hv1 expression in human microglia.

Key Insights and Ideas

  • Hv1 as a Microglial Mitochondrial Regulator: The study strongly implicates Hv1 not just in general microglial activation but specifically in regulating mitochondrial function, particularly the electron transport chain (ETC). This is a novel finding that expands the known roles of Hv1.
  • YHV98-4's Multifaceted Therapeutic Action: The Hv1 inhibitor YHV98-4 doesn't just "turn off" Hv1; it appears to restore a cascade of beneficial effects: reducing oxidative stress, improving ATP production, enhancing mitophagy, and boosting phagocytosis and autophagy. This suggests a central role for Hv1 in a network of microglial functions.
  • Mitochondrial Transfer as a Key Mechanism: The discovery that YHV98-4 enhances microglia-to-neuron mitochondrial transfer is particularly exciting. This suggests that restoring microglial mitochondrial health can directly benefit neurons by providing them with functional powerhouses, a mechanism that could be crucial for neuroprotection in AD.
  • Bridging Innate and Adaptive Immunity: The research highlights how Hv1 in microglia might bridge innate and adaptive immune responses by influencing T cell infiltration, suggesting a broader role in neuroinflammation beyond just microglial activation.

Key Results

  • Hv1 Upregulation in AD: Hv1 expression was significantly upregulated in activated microglia in AD mouse models.
  • Hv1 Inhibition Rescues Mitochondrial Function: Treatment with YHV98-4 reversed tau-induced mitochondrial dysfunction, including reduced oxidative stress, improved mitochondrial membrane potential, increased ATP production, and restored mitophagy.
  • Improved Tau Pathology and Neuroinflammation: YHV98-4 treatment significantly reduced tau pathology (p-tau levels) and neuroinflammation, including decreased ROS production, NOX2 expression, and T cell infiltration.
  • Enhanced Microglia-Neuron Communication: YHV98-4 treatment promoted the transfer of functional mitochondria from microglia to neurons, which was impaired in AD models.
  • Cognitive Improvement: YHV98-4 treatment significantly improved cognitive function in AD mouse models, as demonstrated by performance in MWM, NOR, and Y-maze tests.
  • Therapeutic Potential: YHV98-4 showed therapeutic potential in both tauopathy and amyloid-beta/tau co-pathology AD models.

Limitations and Future Work

  • Mitochondrial Electrophysiology: The authors acknowledge that further validation using mitochondrial electrophysiology is needed to fully understand Hv1's impact on the ETC.
  • Microglia-Specific Hvcn1 Knockout: To precisely pinpoint Hv1's role in microglia, they are generating microglia-specific Hvcn1 knockout mice.
  • Hv1 in T Cells: The study notes that Hv1 is also expressed in T cells, and its role in brain-infiltrated T cells needs further clarification to fully understand its impact on neuroinflammation and neurodegeneration.
  • Precise Transcriptional Mechanisms: Further research is needed to delineate the precise transcriptional mechanisms by which pathways regulate Hvcn1 expression in microglia.
  • Mitochondrial Transfer Mechanisms: While the study shows YHV98-4 enhances mitochondrial transfer, the precise mechanisms (e.g., TNTs, gap junctions, extracellular vesicles) require further investigation.

Summary updated

Abstract

Hyperphosphorylated tau aggregation and neuroinflammation are hallmark pathologies of Alzheimer's disease (AD), with microglia playing a critical role in modulating these processes through maintaining immune homeostasis and clearing pathological tau, both of which depend on mitochondrial health. However, the mechanisms underlying microglial mitochondrial dysfunction in AD remain poorly understood, limiting therapeutic development. Hydrogen voltage-gated channel 1 (Hv1), expressed in microglia within the central nervous system, regulates intracellular pH and reactive oxygen species generation. Here we observe that Hv1 is upregulated in activated microglia in AD mouse models. Remarkably, Hv1 contributes to electron transport chain abnormalities, leading to mitochondrial oxidative stress, loss of mitochondrial membrane potential, impaired ATP production and deficient mitophagy in tau pathology. These deficits impair tau clearance through phagocytosis and autophagy but can be significantly reversed by the Hv1-specific inhibitor YHV98-4. Furthermore, YHV98-4 enhances microglia-to-neuron mitochondrial transfer, promoting the delivery of functional mitochondria to rescue neuronal damage and improve cognitive function. Collectively, our study underscores the pivotal role of Hv1 in microglial mitochondrial dysfunction in AD and identifies YHV98-4 as a promising therapeutic candidate.
BibTeX
@inproceedings{lin2025hv,
  author = {Jiayuan Lin and Huayun Han and Kexin Wu and Xingyu Wu and Juwen Shen and Yiqing Mo and Qiansen Zhang and Huaiyu Yang and Zhihua Yu},
  title = {{Hv1 inhibition rescues AD pathology by restoring microglial mitochondrial function and enhancing mitochondrial transfer}},
  booktitle = {Experimental},
  year = {2025},
  doi = {10.1038/s12276-025-01593-z},
}
Figure